AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02091154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marketing Kit
Description: This marketing tool kit is designed to encourage purchasing of school lunches. The marketing tool kit included the following components:~1. 56''x72'' vinyl sign with the words \[school mascot\] Cafe~2. 8.5''x11'' signs describing the foods offered on a specific day~3. 2''x4'' signs used to name all foods. These were to be placed in a visible location near the corresponding food.~4. Magnetic board displaying a tray onto which magnets shaped as food can be placed to show what foods were being offered during a specific lunch shift.
Study NCT02091154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smarter Lunchrooms Makeover (SLM)
Description: Implement three basic Smarter Lunchrooms techniques. It consists of the following components:~1. Place fruit in an attractive bowl or serving dish and set on two places on the line. One of the places should be at or near the register.~2. Give all vegetables descriptive names and write or type them on a 2''x4'' card. These cards should be visible and placed near the corresponding food.~3. Make white milk the most prominent milk in the milk coolers by making it the most available milk and easiest to take.
Study NCT03540472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
Study NCT01927328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron isomaltoside 1000
Study NCT03704350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: controlled diet
Description: Participants will consume a diet that is controlled in its daily contents of oxalate, calcium, vitamin C and sodium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements (vitamins, calcium or other minerals, herbal supplements, nutritional aids), to exercise strenuously, or to consume food or drink that is not provided to them as part of the controlled diet.
Study NCT03442790 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Agitated Saline Method
Description: All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using agitated saline under ultrasound vision.
Study NCT03442790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Agitated Saline Method
Description: All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using agitated saline under ultrasound vision.
Study NCT03442790 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chest x-ray
Description: All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using chest x-ray obtained in supine position as an active comparator
Study NCT03442790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chest x-ray
Description: All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using chest x-ray obtained in supine position as an active comparator
Study NCT04304976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROBERT®
Description: Robotic Rehabilitation intervention ROBERT®, designed for early, and supplementary therapy of patients.
Study NCT04014036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low energy extracorporeal shockwave therapy
Description: Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
Study NCT04014036 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: low energy extracorporeal shockwave therapy
Description: Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
Study NCT01994239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)
Study NCT01994239 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Radiotherapy
Description: 46 Gy in 23 fractions Prostate only-boost up to 66 Gy
Study NCT01994239 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic Radiotherapy
Description: 46 Gy in 23 fractions Prostate only-boost up to 66 Gy
Study NCT03152279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mucosal Impedance Catheter
Description: During routine endoscopy, consented study participants will have a mucosal impedance catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant.
Study NCT03152279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: At time of endoscopy, subjects with initial positive CeD serology will have a blood sample taken for any missing CeD serologies and intestinal fatty acid-binding protein (IFABP). This will be done at time of IV initiation as to avoid any additional venipuncture.
Study NCT02885948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: used to block the effects of opioids, especially in overdose
Study NCT02885948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, ineffective control arm
Study NCT03341741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin Powder
Description: TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off);
Study NCT03341741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: Colistin solution 2 x daily 1 Mega continuously
Study NCT03341741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: Colistin solution 2 x daily 1 Mega continuously
Study NCT00774813 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nexalin 1.3mA Device
Description: * 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of placebo antidepressant
Study NCT00774813 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nexalin 15mA device
Description: * 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of a placebo antidepressant
Study NCT00774813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo device and Citalopram
Description: * 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of a a SSRI (Citalopram or similar)
Study NCT02412020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA101
Study NCT02412020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PA101
Study NCT02412020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02412020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00805662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin, placebo
Description: intranasal oxytocin during intrauterine insemination
Study NCT02575040 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation to patients with ulcerative colitis and Crohn disease
Study NCT03269643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Group
Description: The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
Study NCT03269643 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reference group
Description: The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
Study NCT00550654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Patients complete a pain assessment questionnaire, Brief Pain Inventory at baseline and at 1 and 3 months after treatment.
Study NCT00550654 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Conformal radiation therapy improves the ability to spare normal tissues.
Study NCT00550654 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: Hypofractionated radiation therapy is delivered to maximize pain relief while minimizing patient impact if life expectancy is short.
Study NCT00550654 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: image-guided radiation therapy
Description: Image guided radiation therapy targets the specific site of disease.
Study NCT00550654 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Tomotherapy is a delivery method which provides megavoltage computed tomography (CT) localization and may provide superior conformality and localization compared to other dynamic intensity modulated radiation therapy techniques.
Study NCT03829241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Troriluzole
Description: 100 mg capsule
Study NCT03829241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole
Description: 100 mg capsule
Study NCT03829241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to troriluzole
Study NCT00698451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin HCL liposome; bevacizumab; carboplatin
Description: 30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
Study NCT01179672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period
Study NCT01179672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period
Study NCT02941653 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Potassium nitrate 2% gel
Description: * Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium nitrate 2% desensitivity gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil)~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes.
Study NCT02941653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potassium oxalate 5% gel
Description: * Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes.
Study NCT04216251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMR101
Description: AMR101-oral predetermined protocol dosage, daily for a minimum of 8 weeks and maximum of 12 weeks
Study NCT01479933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 40 micrograms (1600 IU) per day
Study NCT01479933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo
Study NCT01479933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 80
Description: Vitamin D3 80 micrograms (3200 IU) per day
Study NCT03798678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT03798678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT03798678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenastat Hydrochloride
Description: Given PO
Study NCT03781323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours.
Study NCT01233869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Once daily oral dose of 200 mg of bosutinib
Study NCT01233869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Once daily oral dose of 400 mg of bosutinib transitioned to 200 mg/day
Study NCT01233869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily oral dose of placebo
Study NCT03258125 — intervention group
Intervention type: GENETIC
Intervention: real time PCR (rPCR)
Description: A villus tissue (2.5 cm \* 2.5 cm \* 2.5 cm) will be cut off immediately from the center of placenta, avoiding the area of infarction, bleeding or calcification. After being washed with normal saline, the tissue will be preserved in liquid nitro¬gen at once for subsequent detection of miR-452 and MMP-9 expression by real time PCR (r-PCR). During this procedure total RNA will be extracted including miR-452 and mRNA of MMP-9. Then by reverse transcriptase RNA will be converted into DNA which will be amplification during the PCR, i.e. in real-time, and not at its end, as in conventional PCR. Expression of miR-452 and MMP-9 will be estimated and correlated with each other.
Study NCT00650065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine HCl Tablets 10 mg
Description: 10mg, single dose fasting
Study NCT00650065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec® Tablets 10 mg
Description: 10mg, single dose fasting
Study NCT04235023 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: myeloid PTP1B expression analysis
Description: peripheral blood macrophage PTP1B expression
Study NCT02970734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathe
Description: Six web-based cognitive behavioural therapy sessions. Telephone and email support are also provided during the program.
Study NCT02970734 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resource Webpage
Description: Static webpage listing anxiety resources.
Study NCT00467389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil, 5 mg daily
Description: This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.
Study NCT00467389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Inactive Comparator with Similar Appearance to Active Medication
Study NCT03352011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Brief Mindfulness Training
Description: Primary Care Brief Mindfulness Training consists of four 90-minute group classes that teach sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go.
Study NCT03352011 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PTSD Psychoeducational Class
Description: The PTSD Psychoeducational Class is designed to provide a supportive environment for learning about PTSD-related issues and to help Veterans determine what recovery strategies will be most helpful for them. Session themes include Civilian Readjustment and PTSD, Trust, Safety, and Healing and Treatment Strategies.
Study NCT01338129 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin c
Description: 1000 mg of vitamin c for 45 days
Study NCT01338129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pills
Study NCT02790125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Study NCT02790125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-986166
Study NCT04357145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Dosage Home Exercise Training
Description: By giving more exercise to the experimental group, exercise adherence, pain and functionality will be compared with the standard exercise group.~3 times more reputation than control~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~* Hamstring stretching exercise~* Terminal knee extension exercise~* Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~* Stepping exercise~* Sit up and stand up without support~* Active knee flexion exercise~* Moving forward exercise
Study NCT04357145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dosage Home Exercise Training
Description: 5-6 standard reputations for all exercises~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~* Hamstring stretching exercise~* Terminal knee extension exercise~* Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~* Stepping exercise~* Sit up and stand up without support~* Active knee flexion exercise~* Moving forward exercise
Study NCT01775839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin+Clopidogrel/Digoxin(oral)
Description: oral administration of digoxin
Study NCT01775839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin+Clopidogrel/Digoxin(IV)
Description: intravenous administration of digoxin
Study NCT03508258 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional
Study NCT03508258 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT00533468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Cream 4%
Description: Topical cream, 2g applied under occlusive dressing for 20 minutes prior to the procedure
Study NCT00533468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive placebo without LMX4
Study NCT01187849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Volunteers will be given Metformin or placebo for 1 month, once daily.
Study NCT01187849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers will be given Metformin or placebo for 1 month, once daily
Study NCT01951781 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: blood sample in newborn preterms suspected of nosocomial infection (neoCD64 arm)~When late-onset sepsis is suspected, blood samples are obtained from peripheral veins for a complete blood count, measurement of CRP and PCT concentration and one bacterial culture acording to the current recommendation of the CDC. CD64 concentration measurement require 0.2 ml aditionnal blood.
Study NCT04112446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium
Description: On Day 1, subjects will receive a single oral dose of \[14C\]-saroglitazar magnesium
Study NCT03836820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pilates exercise
Description: Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
Study NCT03836820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.
Study NCT03836820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pilates and Aerobic Exercise
Description: Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.
Study NCT03255057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemolung Respiratory Assist System
Description: Treatment with a medical device called the Hemolung RAS. The Hemolung RAS includes three components: the Hemolung Controller, the Hemolung Cartridge, and the Hemolung Catheter. The intervention is use of the Hemolung RAS to provide partial lung support for acute hypercapnic lung failure by filtering carbon dioxide from venous blood using a central venous catheter through which venous blood is pumped at flows of 350-550 milliliters per minute to and from an external circuit containing a hollow fiber membrane blood gas exchanger (with heparin-coated fibers) integrated with a centrifugal pump.
Study NCT03255057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Description: Lung support for acute lung failure applied with a mechanical ventilation device that uses positive pressure to mechanically inflate the lungs and facilitate exhalation via an endotracheal tube or tracheotomy.